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Th cells recognize and respond to processed antigen bound to class II MHC mol-
ecules on the surfaces ofAPC (1, 2). In vitro, the targeting of antigen to APC surfaces
by heterocrosslinked bispecific antibodies (HBAs)' greatly increases the efficiency
with which APC endocytose, process, and present antigen to T cells (3-5). Since
antibody responses against most protein antigens require T cell help in vivo, we
have asked here if HBAs could also enhance the ability of an antigen, in this case
hen egg lysozyme (HEL), to induce an antibody response in mice. HBAs were pre-
pared by chemically crosslinking an antibody with specificity for HEL to various
other antibodies, each specific for a particular APC cell surface component. Nor-
mally, the generation of immune responses after immunization with vaccines and
other antigens requires relatively large amounts ofantigen, multiple injections, and,
in experimental animals, adjuvants (6, 7). By contrast, we show that HBAs, when
administered once with nanogram amounts of antigen, in the absence of adjuvant,
induce high titers of antibody in mice, and prime mice for a secondary IgG anti-
body response when rechallenged with soluble antigen.
Materials and Methods
Immunizations and Measurements ofAntibody Production.
￿
Mice of various strains were given
primary injectionscontaining various amounts ofHEL (Sigma Chemical Co., St. Louis, MO)
or HEL mixed with 5-10 ug of HBA in PBS, in two portions of 50 1.I in each hind footpad.
Controls received PBS alone. Mice were bled 21 d after the primary injection, and the next
day given a secondary challenge of 5-10 jig of HEL (5,ug per hind footpad). 11 d later, the
mice were bled again, sera were isolated, and anti-HEL IgG antibody was measured using
a solid-phase ELISA. In the ELISA, HEL was bound to plastic microtiterwells and incubated
sequentially with dilutions of each test serum, biotin anti-mouse IgG (Southern Biotech-
nology Assoc., Birmingham, AL), avidin-alkaline phosphatase (Sigma Chemical Co.), and
finally, substrate (Sigma Chemical Co.). The amount of antibody in each serum was interpo-
lated from the dose-response curve of a standard pool of hyperimmune sera, giving an ar-
bitrary value of antibody U/ml.
Antibodies.
￿
All HBAs used in this paper were prepared by chemically crosslinking mAbs
with succinimidyl-3-(2 pyridyldithiol)propionate as described (8). HBAs were separated from
uncrosslinked monomeric antibodies by gel filtration and are designated "antibody 1 x anti-
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body 2." For example, anti-I-A' x anti-HEL refers to a gel filtration fraction of 300 kD or
greater, obtained when anti-I-A' was crosslinked to anti-HEL. Antibodies used in this paper
are anti-HEL, HyHEL-8 (9); anti-I-Ak, 10-2.16 (10); anti-I-Ad, MKD6 (11); anti-KkDd, 34.1.2
(12) ; anti-Kk, 36.7.5 (12); anti-FcyRII, 2AG2 (13); anti-IgDa, AM628.1 (14); and anti-IgD',
AF3-33.3 (14). Fab fragments were produced by papain digestion and were purified by gel
filtration followed by ion exchange chromatography (15).
Results and Discussion
Female A/J mice were given subcutaneous injections of graded amounts of HEL
or HEL mixed with HBAs, on day 0. 21 d later, the mice were bled to determine
serum anti-HEL IgG antibody levels. On day 22, the mice were given booster injec-
tions of 5 ttg ofHEL per hind foot pad, to induce secondary IgG antibody responses .
Sera were collected 11 d later and IgG antibody was measured. Fig. 1 shows that
>10 Ag of HEL per mouse was required in a primary injection to produce either
a primary or a secondary IgG antibody response, if the HEL was given alone. How-
ever, in the presence of 10 Wg of HBA (anti-I-A' x anti-HEL), 100 ng of HEL in-
duced a substantial primary IgG antibody response, and as little as 10 ng of HEL
induced a strong secondary response. In other experiments (e.g., Fig. 2), <1 ng of
HEL in the presence of HBA gave a significant secondary response. Mice receiving
PBS as a primary injection, and then given a secondary challenge of HEL (Fig.
1), or given the HBA alone as a primary injection and then a secondary challenge
of HEL (Fig. 2), produced little or no IgG antibody. We compared immunization
using HBAs with that of HEL emulsified in IFA (Fig. 2). The two types of immuni-
zation produced similar amounts of IgG antibody in the secondary response, espe-
cially at low HEL doses. Thus, the HBA specific for HEL and class II MHC struc-
tures increased the efficiency of immunization by 300-fold in the primary response,
and by a factor of 103 to 104 after a secondary boost. The HBA increased the
efficiency of priming for secondary IgG antibody responses at least as well as IFA.
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FIGURE 1.
￿
HBA enhancement of anti-
body responses in vivo. Groups of three
female, 7-wk-old A/J mice were given sin-
gle primary foot pad injections of(A) HEL
alone or (B) HEL mixed with 10 jig HBA.
The open bars indicate serum IgG anti-
HEL antibody levels 21 d afterthe primary
injection. The solid bars indicate antibody
levels in sera taken 11 d after these same
mice were given a secondary injection of
10 fAg HEL without the HBA. The dashed



















duction by HBAandIFA. Secondaryantibody
responsesareshownforgroups,offour female,
6-wk-old B10.A mice givenprimaryinjections
of HEL mixedwith 10 Ftg HBA(solid bars)or
emulsified (1 :1 [vol/vol]) in IPA(oats-hatched
bars). Control mice (open bar) received HBA
butno HELas aprimaryinjection. Thehor-
izontal dashed line indicates the limitof de-
tection of antibody.
on variousAPC, and used themto immunize mice (Table I). HBAsspecific forclass
I or class II MHC molecules, or FcyRII, all enhanced the ability ofHEL to induce
antibody responsesin different strains ofmice. However, two HBAswith specificity
for two allotypes of IgD when tested in several strains ofmice induced little or no
anti-HEL antibody (Table I, Exp. 2). In other experiments (not shown), we were
unable to generate a significant anti-HEL response by varying the dosages of the
IgD-specific HBAs andHELfrom 20 to 0.1 Wg. These same IgD-specific HBAs en-




HBA with Specificity for Class I or 11 MHC Molecules andfor FcyRII,
but notfor s1gD, Enhance Hurnoral Responses Against HEL
Groups of 4-5 female mice of different strains were givenprimaryinjections of2 wg of HEL
with or without 10 Kg of HBA, having the indicated specificities. After 21 d, each mouse
was given a second injection of 10 ug of HEL in PBS. Sera were collected 11-13 d later,
and anti-HEL IgG antibody was measured and is shown as U/ml. The limits of detection
were 7,000 U/ml for Exp. 1 and 2,000 U/ml for Exp. 2.









CAF1 ddd x kkd - 7(0)' 7(0)
Anti-I-Ak x anti-HEL 8(1) 166(60)
Anti-KdDd x anti-HEL 7(0) 33(11)
Anti-FcyRII x anti-HEL 8(1) 40(15)
A/J kkd - ND 9(4)
Anti-I-Ak x anti-HEL 63(15) 933(200)
Anti-Kk x anti-HEL 14(12) 302(115)
Anti-FcyRII x anti-HEL 13(11) 269(70)
CAFI ddd x kkd - 2(0) 3(2)
Anti-I-Ak x anti-HEL 19(6) 118(14)
Anti-IgDB x anti-HEL 2(0) 9(4)
B10.BR kkk - 2(0) 3(0)
Anti-I-Ak x anti-HEL 19(10) 39(5)
Anti-IgDB x anti-HEL 3(1) 12(2)1960
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(4). The inability of anti-sIgD-containing HBAs to enhance immunogenicity sug-
gests that either these HBA antigen complexes, when given subcutaneously, do not
bind to B cells in vivo (e.g., they might be cleared rapidly or circulating IgD might
block their binding to B cells), or that B cells are not able to stimulate unprimed
Tcells invivo. B cells appear toserveasin vivo APCto stimulateT cellproliferation
in other systems (16-20).
Several important controls for the effect of HBAs are shown in Table II. First,
HBAs enhancedantibody productiononlyifthe appropriate antibodies were in fact
crosslinked; monomeric mixtures ofantibodies did not work (Table II, Exp. 1). Second,
antibody was induced only if the strain ofmouse immunized expressed the struc-
tures to which the HBA could bind (Table II, Exp. 2). Thus, HBAs with I-Ad or
KdDd specificities did not produce responses in H-2k (C3H) mice, but did produce
responses in H-2k x H-2d (CAFI) mice. The same I-Ad-specific HBA did not in-
duce antibody in A/J mice, but the KdDd-specific HBA did, since this strain ex-
presses Dd but not I-Ad. Both the C3H and the A/J mice responded when im-
munized with the HEL- and FcyRII-specific HBA.
Because antigen targeted to FcyRII gave enhanced antibody responses to HEL
in several strains, itwas important to show that the HBAs were not simply forming
immune complexes with HEL and binding via their Fc portions to FcYR on APC.
Therefore, we constructed an HBA from Fab fragments ofanti-HEL and anti-I-Ak
mAbs, and compared its ability to induce anti-HEL antibody with that ofits intact
Ig counterpart (Table II, Exp. 3). The results show that the Fab-HBA performed
as well as the intact Ig-HBA over a range ofdosages, indicatingthat the Fc regions
ofthe HBA were not required for enhanced antibody production. This conclusion
is also supported by the observation that anti-H-2d-specific HBAs did not promote
antibody production in H-2k (i.e., C3H) mice (Table II, Exp. 2).
It is likely that HBAs increase anti-HEL production in mice by targeting HEL
to surface structures on APC in vivo. Such targeting would cause the antigen to
beprocessed andpresented to Tcells with muchhigher efficiency than antigen given
alone, as documented in vitro (3-5). Presumably, such APC could then generate
large numbers of antigen-specific Th cells, which in turn would stimulate antigen-
specific B cells. The known T cell dependence ofanti-HEL responses in mice (21,
22) supports this view.
Ouruse ofHBAsto enhanceimmunization follows on previous results (18, 23-25),
showingthat antigens that were chemically crosslinked directly to antibodies specific
for class II MHC or IgM molecules were more potent immunogens than antigens
given alone. HBAs provide several important advantages over chemically linked
antigen-antibody conjugates. First, HBAs couldbeused toenhance responses against
small amountsofimpure antigens, forexample, tumor antigens, whereasdirect linkage
ofantigen to antibody requires relatively large amounts ofhighly purified antigen.
HBAs do not require biochemicalmodification ofantigen, whichcould alter its im-
munogenicity. In addition, bispecific antibodies in the form ofhybrid-hybridomas
(26, 27) or hetero-F(ab')2 (28) can be prepared as single homogeneous species,
whereas antibody-antigen chemical complexesare heterogeneous, and vary between
preparations. Therefore, homogeneous bispecific antibodies would be much more
suitable for large scale production than the antigen-antibody chemical complexes.
Finally, we have found that the microgram amounts ofHBAsused in this study areSNIDER ET AL.
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Groups of female mice (4-5 per group) were injected with the indicated doses of HEL or antibody. In
Exp. 1, the effect of HBAs on the anti-HEL antibody response was compared with that of the uncross-
linked fraction (mix) obtained during purification of HBAs, and to that of the anti-HEL mAb alone. In
Exp. 2, the specificity of targeting was tested in mouse strains that express structures to which particular
HBAs bind or do not bind. C3H/HeJ and A/J mice were also immunized with HEL plus an anti-FcyRII-
specific HBA as a control for their ability to respond to targeted HEL. The isotypes and allotypes of anti-
bodies used in this experiment were as follows: anti-I-Ad (MKD6), mouse IgG2a, IgHl-b or -e (strain
of origin, B6 x A/J); anti-KdDd (34.1 .2), mouse IgG2a, IgHl-j (strain of origin, C3H); anti-HEL
(HyHEL-8), mouse IgG1, IgH4-a (strain oforigin, BALB/C); anti-FcyRII (2.4G2), rat IgG26. There is
no obvious relationship between possible alloreactivities against HBAs and their ability to enhance anti-
HEL production. In Exp. 3, anti-I-Ak x anti-HEL HBAs prepared from intact antibodies or from Fab
fragments were compared for their ability to induce anti-HEL antibody. In all experiments, mice were
bled 11-14 d after a secondary injection of 10 l;g of HEL in PBS. Data are mean U/ml of serum IgG
antibody. The limits ofdetection were 7,000 U/ml (Exp. 1), 3,000 U/ml (Exp . 2), and 1,000 U/ml (Exp. 3).
Figures in parentheses are SEM.
remarkably potent enhancersofimmunogenicity, leadingto primingwithnanogram
amounts of antigen. Such enhancements of immunogenicity are far greater than
those reported in studies using antigen-antibodychemical complexes. Our observa-
tions thatrelatively small amounts ofHBAs canenhanceantibody responses at least
as well as IFA suggests that HBAs may beuseful in immunizingman and domestic
animals against bacterial, viral, parasitic, and, perhaps, tumor antigens. Such im-
Antibody (form) Ab dose
ls8
Secondary response:
HEL dose IgG anti-HEL
Fig U/ml x 10-3
Anti-I-Ak x anti-HEL (HBA) 5 1 250(59)'
Anti-I-Ak + anti-HEL (mix) 5 1 9(3)
Anti-FcyRII x anti-HEL (HBA) 5 1 120(21)
Anti-FcyRII x anti-HEL (mix) 5 1 11(2)
Anti-HEL (mAb) 2 .5 1 10(3)
None 0 1 11(6)
None 0 0 7(0)
Anti-I-Ad x anti-HEL (HBA) 10 3 240(65)
Anti-KdDd x anti-HEL (HBA) 10 3 174(70)
None 0 3 3(0)
Anti-I-Ad x anti-HEL (HBA) 10 3 8(4)
Anti-KdDd x anti-HEL (HBA) 10 3 5(3)
Anti-FcyRII x anti-HEL (HBA) 10 3 245(95)
None 0 3 11(5)
Anti-I-Ad x anti-HEL (HBA) 10 3 18(9)
Anti-KdDd x anti-HEL (HBA) 10 3 112(69)
Anti-FcRyRII x anti-HEL (HBA) 10 3 302(122)
None - 3 13(2)1962
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munization would be efficient and would avoid the use of adjuvants that have un-
wanted inflammatory effects (29), and cannot, therefore, be used in humans.
Summary
The binding of protein antigens to APC with heterocrosslinked bispecific anti-
bodies (HBAs) enhances their processing and presentation to Th cells in vitro. Here
we have asked whether HBAs could also increase immune responses in vivo. We
immunized mice with hen egg lysozyme (HEL) in the presence or absence of HBA,
and followed antibody production after the primary challenge and after a secondary
boost. We found that HBAs that bind antigen to MHC class I or II molecules, to
FoyR, but not to surface IgD, enhance the immunogenicity of HEL. HBAs that
bound HEL to MHC class II molecules, for examples, decreased the amount of
antigen required to elicit a primary anti-HEL antibody response in mice by 300-
fold, and the amount required to prime for a secondary response by 103- to 10'-
fold. In fact, HBAs were as effective as IFA in generating antibody responses. Since
adjuvants cannot be used in humans, HBAs could prove useful for immunizing people,
especially in cases where, due to scarcity or toxicity, minute doses of antigen must
be used.
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